SEC Comment Letter 0000000000-23-003549 to OS Therapies Inc (OSTX)
OS Therapies Inc
Date: April 10, 2023 · CIK: 0001795091 · Accession: 0000000000-23-003549
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271034
Letter
United States securities and exchange commission logo April 10, 2023 Paul A. Romness, MPH President and Chief Executive Officer OS Therapies Incorporated 15825 Shady Grove Road, Suite 135 Rockville, Maryland 20850 Re:OS Therapies Incorporated Registration Statement on Form S-1 Filed March 31, 2023 File No. 333-271034 Dear Paul A. Romness: We have reviewed your registration statement and have the following comment. In this comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Registration Statement on Form S-1 Phase 1B Clinical Trial, page 3 1.We note your revised disclosure on page 69 in response to Comment 5. Please revise the disclosure on page 3 to highlight that no objective tumor response (complete or partial) was observed in the trial.
FirstName LastNamePaul A. Romness, MPH Comapany NameOS Therapies Incorporated April 10, 2023 Page 2 FirstName LastName Paul A. Romness, MPH OS Therapies Incorporated April 10, 2023 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. You may contact Christine Torney at 202-551-3652 or Lynn Dicker at 202-551-3616 if you have questions regarding comments on the financial statements and related matters. Please contact Jimmy McNamara at 202-551-7349 or Joe McCann at 202-551-6262 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Spencer G. Feldman
Show Raw Text
United States securities and exchange commission logo
April 10, 2023
Paul A. Romness, MPH
President and Chief Executive Officer
OS Therapies Incorporated
15825 Shady Grove Road, Suite 135
Rockville, Maryland 20850
Re:OS Therapies Incorporated
Registration Statement on Form S-1
Filed March 31, 2023
File No. 333-271034
Dear Paul A. Romness:
We have reviewed your registration statement and have the following comment. In this
comment, we may ask you to provide us with information so we may better understand your
disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments.
Registration Statement on Form S-1
Phase 1B Clinical Trial, page 3
1.We note your revised disclosure on page 69 in response to Comment 5. Please revise the
disclosure on page 3 to highlight that no objective tumor response (complete or partial)
was observed in the trial.
FirstName LastNamePaul A. Romness, MPH
Comapany NameOS Therapies Incorporated
April 10, 2023 Page 2
FirstName LastName
Paul A. Romness, MPH
OS Therapies Incorporated
April 10, 2023
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
You may contact Christine Torney at 202-551-3652 or Lynn Dicker at 202-551-3616 if
you have questions regarding comments on the financial statements and related matters. Please
contact Jimmy McNamara at 202-551-7349 or Joe McCann at 202-551-6262 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Spencer G. Feldman